Enstilar® leads to visible signs of improvement in adult plaque psoriasis, from baseline, as early as week 11
In the phase III, double-blind, randomised, vehicle-controlled PSO-FAST study:1
Adapted from Leonardi et al. J Drugs Dermatol 2015.
*Treatment success according to PGA was defined as clear or almost clear from baseline for patients with moderate/severe disease and clear from baseline for those with mild disease.1,2
†Absolute reduction in mean mPASI of 2.8 at week 1 and 5.4 at week 4.1
CI: confidence interval; OR: odds ratio; PASI: psoriasis area severity index; PGA: physician’s global assessment